|本期目录/Table of Contents|

[1]郭睿婷,曹芯萍,张祎,等.嵌合抗原受体T细胞与不同放疗方式协同治疗大肿块型淋巴瘤的研究[J].天津医科大学学报,2024,30(04):310-315,322.[doi:10.20135/j.issn.1006-8147.2024.04.0310]
　GUO Ruiting,CAO Xinping,ZHANG Yi,et al.Chimeric antigen receptor T cells synergize with different radiotherapy modalities for the treatment of bulky lymphoma[J].Journal of Tianjin Medical University,2024,30(04):310-315,322.[doi:10.20135/j.issn.1006-8147.2024.04.0310]
点击复制

嵌合抗原受体T细胞与不同放疗方式协同治疗大肿块型淋巴瘤的研究(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
30卷
期数:
2024年04期
页码:
310-315,322
栏目:
肿瘤疾病专题
出版日期:
2024-07-10

文章信息/Info

Title:
Chimeric antigen receptor T cells synergize with different radiotherapy modalities for the treatment of bulky lymphoma
文章编号:
1006-8147(2024)043-0310-07
作者:
郭睿婷1; 曹芯萍1; 张祎1; 赵一帆1; 赵明峰2; 肖霞2
（1. 天津医科大学一中心临床学院，天津300192；2. 天津市第一中心医院血液科，天津300192）
Author(s):
GUO Ruiting1; CAO Xinping1; ZHANG Yi1; ZHAO Yifan1; ZHAO Mingfeng2; XIAO Xia2
（1.The First Central Clinical School，Tianjin Medical University，Tianjin 300192，China； 2.Department of Hematology，Tianjin First Central Hospital，Tianjin 300192，China）
关键词:
淋巴瘤; 淋巴瘤; B细胞; 放射疗法; 免疫疗法; 过继
Keywords:
lymphoma; lymphoma; B-cell; radiotherapy; immunotherapy; adoptive
分类号:
R733.4
DOI:
10.20135/j.issn.1006-8147.2024.04.0310
文献标志码:
A
摘要:
目的：探索不同放疗方式与嵌合抗原受体T（CAR-T）细胞协同治疗大肿块型淋巴瘤的疗效。方法：建立大肿块型淋巴瘤异种移植小鼠模型，使用低、中、高剂量的X射线对小鼠进行照射，测量照射后各组小鼠肿瘤体积的变化情况。再将低、中、高剂量的X射线分别与CAR-T细胞联用对小鼠进行治疗，记录不同的联用方式治疗后肿瘤体积的变化情况和各组小鼠的生存时间，使用流式细胞术检测各组小鼠外周血和肿瘤内CAR-T细胞占比的差异，观察治疗后各组小鼠的不良反应。结果：单纯X射线治疗无法控制巨块型淋巴瘤小鼠的肿瘤进展，而分别将低、中、高剂量的X射线与CAR-T细胞联用则均能使小鼠的肿瘤体积缩小。与低剂量联合组相比，中、高剂量联合组小鼠的肿瘤体积缩小更显著且未见重新增大的迹象（F组间=1 052.364，F时间=14 861.095，F交互=49.864，均P＜0.001；组间均P＜0.05），此外，中剂量联合组[HR=21.880（3.884~124.600） ，Log-rank?字２=12.090，P＜0.01]和高剂量联合组[HR=21.880（3.884~124.600），Log-rank?字２=12.090，P＜0.01]小鼠生存期也均明显延长。中、高剂量X射线可能更利于CAR-T细胞的瘤内浸润，与低剂量联合组相比，中（t=28.200，P＜0.05）、高（t=23.960，P＜0.05）剂量联合组在治疗后第14天的瘤内CAR-T细胞比例均明显增加。不同联用方式的不良反应大多在可耐受范围内。结论：与低剂量X射线相比，中、高剂量X射线能与CD19 CAR-T细胞协同更有效地治疗大肿块型淋巴瘤。
Abstract:
Objective： To explore the efficacy of different radiotherapy modalities in synergistic treatment of bulky lymphoma with chimeric antigen receptor T （CAR-T） cells. Methods：The bulky lymphoma xenograft mice models were established，which were irradiated with low，medium and high doses of X-rays. The changes in the tumor volume of the mice in each group were measured after irradiation. After that，the low，medium and high doses of X-rays were combined with CAR-T cells to treat the mice，and the changes in tumor volume and the survival time of those mice in each group were recorded after different combination treatments. Flow cytometry was used to detect the differences in the percentage of CAR-T cells in the peripheral blood and tumors of the mice in each group，and the adverse reactions of the mice in each group were observed after treatment. Results：X-ray treatment alone was unable to control tumor progression in mice with bulky lymphoma，whereas combining low，medium，and high doses of X-rays with CAR-T cells，respectively，all resulted in a reduction in tumor size. Compared with the low-dose combination group，mice in the medium- and high-dose combination groups showed more significant reduction in tumor volume，which showed no signs of re-enlargement，either（Fbetween groups=1 052.364，Ftime=14 861.095，Finteraction=49.864，all P＜0.001； P＜0.05 for all between groups）. In addition，the survival period of mice in the medium-dose combination group[HR=21.880（3.884-124.600），Log-rank?字２=12.090，P＜0.01] and high-dose combination group [HR=21.880（3.884-124.600），Log-rank?字２=12.090，P＜0.01] were also significantly prolonged. Medium- and high-dose X-rays might be more favorable for intratumoral infiltration of CAR-T cells. The proportion of intratumoral CAR-T cells was significantly increased in both the medium（t=28.200，P＜0.05） and high（t=23.960，P＜0.05） dose combination groups on day 14 post-treatment compared to the low-dose combination group. Most of the adverse effects of the different combination modalities were within the tolerable range. Conclusion：Compared to low-dose X-rays，medium- and high-dose X-rays can synergize with CD19 CAR-T cell therapy to more effectively treat bulky lymphoma.

参考文献/References:

[1] 张锡友，李丹丹，陈峰，等. Car-T治疗B细胞淋巴瘤疗效研究的Meta分析[J]. 天津医药，2018，46（12）：1330-1335.
[2] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）淋巴瘤诊疗指南[M]. 北京： 人民卫生出版社，2023：1-297.
[3] 肖霞，袁婷，孟娟霞，等. CD19嵌合抗原受体T细胞治疗复发难治B细胞淋巴瘤患者效果不佳的因素分析[J]. 中华医学杂志，2020，100（8）：593-598.
[4] ALARCON T A，FEIN J A，FRIED S，et al. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma[J]. Leukemia，2022，37（1）：154-163.
[5] BROOKS E D，FANG P，PINNIX C C. Salvage radiotherapy for primary refractory and relapsed diffuse large B-Cell lymphoma[J]. Br J Radiol，2021，94（1127）：20210360.
[6] TURGEON G A，WEICKHARDT A，AZAD A A，et al. Radiotherapy and immunotherapy： a synergistic effect in cancer care[J]. Med J Aust，2019，210（1）：47-53.
[7] WEISS T，WELLER M，GUCKENBERGER M，et al. NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma[J]. Cancer Res，2018，78（4）：1031-1043.
[8] ZHANG Y，DING Z，PERENTESIS J P，et al. Can rational combination of ultra-high dose rate FLASH radiotherapy with immunotherapy provide a novel approach to cancer treatment?[J].Clin Oncol（R Coll Radiol），2021，33（11）：713-722.
[9] 柴笑，金鑫，赵明峰. 靶向CLL-1嵌合抗原受体T细胞的构建及其功能验证[J]. 中华血液学杂志，2022，43（2）：102-106.
[10] 肖霞.改进的放疗分割方式联合 CAR-T 细胞治疗 B 细胞淋巴瘤的作用研究[D].天津医科大学，2022.
[11] 韩为东，张亚晶. CAR-T细胞治疗淋巴瘤——我们仍然在路上[J]. 临床血液学杂志，2022，35（9）：612-615.
[12] 赵培起，张会来. 嵌合抗原受体T细胞免疫疗法在B细胞非霍奇金淋巴瘤中的研究进展[J]. 天津医药，2020，48（1）：71-75.
[13] STERNER R C，STERNER R M. CAR-T cell therapy： current limitations and potential strategies[J]. Blood Cancer J，2021，11（4）：69.
[14] TOKOLA S，KUITUNEN H，TURPEENNIEMI-HUJANEN T，et al. Significance of bulky mass and residual tumor-treated with or without consolidative radiotherapy-to the risk of relapse in DLBCL patients[J]. Cancer Med，2020，9（6）：1966-1977.
[15] HERRERA F G，IRVING M，KANDALAFT L E，et al. Rational com-binations of immunotherapy with radiotherapy in ovarian cancer[J]. Lancet Oncol，2019，20（8）：e417-e433.
[16] TURCHAN W T，PITRODA S P，WEICHSELBAUM R R. Radiotherapy and immunotherapy combinations in the treatment of patients with metastatic disease： current status and future focus[J]. Clin Cancer Res，2021，27（19）：5188-5194.
[17] SAIFI O，LESTER S C，BREEN W G，et al. Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma： a multicenter consensus approach[J]. Am J Hematol，2024，99（1）：124-134.
[18] HOVHANNISYAN L，RIETHER C，AEBERSOLD D M，et al. CAR T cell-based immunotherapy and radiation therapy： potential，pro-mises and risks[J]. Mol Cancer，2023，22（1）：82.
[19] NG A K，YAHALOM J，GODA J S，et al. Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma： guidelines from the International Lymphoma Radiation Oncology Group[J]. Int J Radiat Oncol Biol Phys，2018，100（3）：652-669.
[20] QU C，PING N，KANG L，et al. Radiation priming chimeric antigen receptor T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma with high tumor burden[J]. J Immunother，2020，43（1）：32-37.
[21] DUTT S，ATALLAH M B，MINAMIDA Y，et al. Accelerated，but not conventional，radiotherapy of murine B-cell lymphoma induces potent T cell-mediated remissions[J]. Blood Adv，2018，2（19）：2568-2580.
[22] 王玉洁，王桃，杨建民. 嵌合抗原受体T细胞免疫疗法预处理方案的研究进展[J]. 国际输血及血液学杂志，2020，43（1）：77-81.

相似文献/References:

[1]何广辉,孙丰源.白藜芦醇对淋巴瘤BJAB细胞体外增殖及细胞周期作用的研究[J].天津医科大学学报,2014,20(05):360.
　HE Guang-hui,SUN Feng-yuan.Effects of resveratrol on the proliferation and cell cycle of lymphoma BJAB cell in vitro[J].Journal of Tianjin Medical University,2014,20(04):360.

备注/Memo

备注/Memo:
基金项目： 天津市卫生健康委员会科技项目 （ZC20074）
作者简介： 郭睿婷（1998-），女，硕士在读，研究方向：血液系统恶性肿瘤的细胞免疫疗法；
通信作者：肖霞，E-mail：xxiiaao@126.com。
更新日期/Last Update: 2024-07-10